Inventor · disambiguated record
Mark Bonyhadi
Also filed as: BONYHADI MARK · BONYHADI MARK L
16 granted patents·28 pending applications·3,267 citations·filing 1993–2025
95Inventor score
Files withJUNO THERAPEUTICS INC15XCYTE THERAPIES INC15INVITROGEN CORP4LIFE TECHNOLOGIES CORP4SYSTEMIX INC3
Top patents by PatentIndex Score
44 records- 0197US7977095B2Generation and isolation of antigen-specific T cellsLIFE TECHNOLOGIES CORP·Filed 2008·Granted Jul 12, 2011·57 cites·14 claims
- 0297US6905874B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2001·Granted Jun 14, 2005·950 cites·43 claims
- 0397US6867041B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2002·Granted Mar 15, 2005·935 cites·21 claims
- 0497US6797514B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2001·Granted Sep 28, 2004·985 cites·14 claims
- 0596US9528088B2Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulationLIFE TECHNOLOGIES CORP·Filed 2013·Granted Dec 27, 2016·35 cites·6 claims
- 0696US7572631B2Activation and expansion of T cellsINVITROGEN CORP·Filed 2005·Granted Aug 11, 2009·217 cites·7 claims
- 0795US8617884B2Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulationBERENSON RONALD J·Filed 2008·Granted Dec 31, 2013·37 cites·6 claims
- 0894US12208137B2Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2023·Granted Jan 28, 2025·4 cites·10 claims
- 0994US11400115B2Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Aug 2, 2022·18 cites·28 claims
- 1093US12296010B2Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·1 cites·20 claims
- 1190US2025387482A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1280US2023090176A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1379US7541184B2Activation and expansion of cellsINVITROGEN CORP·Filed 2004·Granted Jun 2, 2009·10 cites·2 claims
- 1478US2024368625A1Methods and compositions for preparing genetically engineered cellsJUNO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1575US2025152712A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1675US2025161450A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1775US2025161449A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1872US12258580B2Process for generating therapeutic compositions of engineered cellsJUNO THERAPEUTICS INC·Filed 2018·Granted Mar 25, 2025·2 cites·41 claims
- 1966US2020071663A1Methods for eliminating at least a substantial portion of a clonal antigen-specific memory t cell subpopulationLIFE TECHNOLOGIES CORP·Filed 2019·Application pending·0 cites
- 2065US2024158837A1Epigenetic analysis of cell therapy and related methodsJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2165US2010092436A1Compositions and methods for restoring immune responsiveness in patients with immunological defectsBONYHADI MARK·Filed 2009·Application pending·0 cites
- 2262US2005153447A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 2362US2005214942A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 2459US2005084967A1Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantationXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 2558US2017114321A1Methods for eliminating at least a substantial portion of a clonal antigen-specific memory t cell subpopulationLIFE TECHNOLOGIES CORP·Filed 2016·Application pending·0 cites
- 2658US2007274974A1Compositions and methods for restoring immune responsiveness in patients with immunological defectsINVITROGEN CORP·Filed 2007·Application pending·0 cites
- 2758US2007212767A1Generation and isolation of antigen-specific t cellsINVITROGEN CORP·Filed 2007·Application pending·0 cites
- 2857US2020239910A1Methods and compositions for preparing genetically engineered cellsJUNO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2956US2003119185A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2002·Application pending·0 cites
- 3054US11821027B2Epigenetic analysis of cell therapy and related methodsJUNO THERAPEUTICS INC·Filed 2018·Granted Nov 21, 2023·0 cites·29 claims
- 3154US2004175373A1Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantationXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 3254US2006286089A1Compositions and methods for the treatment of burns and sepsisXCYTE THERAPIES INC·Filed 2006·Application pending·0 cites
- 3354US2004224402A1Generation and isolation of antigen-specific T cellsXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 3453US2025171739A1Process for generating therapeutic compositions of engineered cellsJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3552US2004005298A1Compositions and methods for restoring immune responsiveness in patients with immunological defectsXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 3649US2003082806A1Maturation of antigen-presenting cells using activated T cellsXCYTE THERAPIES INC·Filed 2002·Application pending·0 cites
- 3745US5612018ADrug screening and treatment for HIV thymocyte depletionSYSTEMIX INC·Filed 1994·Granted Mar 18, 1997·8 cites·7 claims
- 3845US2020297760A1Compositions and methods for reducing immune responses against chimeric antigen receptorsJUNO THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3944US2004151704A1Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantationXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 4042US2003235908A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 4142US2005226857A1T cell therapy for the treatment of cachexia and chronic diseasesXCYTE THERAPIES INC·Filed 2005·Application pending·0 cites
- 4237US5601975AMethod for screening potential therapeutically effective antiviral agentsSYSTEMIX INC·Filed 1995·Granted Feb 11, 1997·5 cites·10 claims
- 4332US5645982AMethod for screening potential therapeutically effective antiviral agentsSYSTEMIX INC·Filed 1993·Granted Jul 8, 1997·3 cites·14 claims
- 4428US2003022210A1T cell induced tissue repair and regenerationFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Bonyhadi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →